Artelo Biosciences announced that a peer‑reviewed article was published in the European Journal of Pain, providing preclinical evidence for its FABP5 inhibitor ART26.12. The study, authored by Artelo scientists, demonstrates analgesic effects across visceral, inflammatory, neuropathic, and joint pain models.
The publication follows seven prior preclinical studies that showed ART26.12 activity in diabetic neuropathy, osteoarthritis, cancer bone pain, and chemotherapy‑induced peripheral neuropathy. The new data reinforce the company’s claim that FABP5 inhibition offers a novel, non‑opioid mechanism for pain management.
The article also notes that a Phase 1 single‑ascending‑dose (SAD) study was completed with no severe or serious drug‑related adverse events, and that a multiple‑ascending‑dose (MAD) clinical trial is planned for later in 2026. The SAD results provide a safety foundation for the upcoming MAD study.
Dr. Andrew Yates, Artelo’s Chief Scientific Officer, said the peer‑reviewed publication strengthens the scientific foundation for ART26.12 and reinforces the company’s view that FABP5 inhibition represents a first‑in‑class approach to pain relief. The study’s findings are expected to support future partnership or investment discussions as ART26.12 moves toward human testing.
The announcement was well received by investors, reflecting confidence in the company’s scientific progress and its ability to maintain Nasdaq listing compliance after a recent compliance extension. The publication also highlights Artelo’s broader pipeline, which includes ART27.13 for glaucoma and ART12.11 for anorexia and other indications.
With the peer‑reviewed data now publicly available, Artelo’s next milestones include the MAD trial launch and continued progress on its other pipeline candidates. The company’s focus on a non‑opioid pain platform positions it to address a significant unmet need in the pain therapeutics market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.